In a trial by the end of a study period of more than 2,200 young people in the US, none of them had been vaccinated against COVID-19, Pfizer said in a statement. The results show that the Pfizer-BioNTech vaccine may be more effective for 12- to 15-year-olds than it does for adults.
Pfizer has not yet released the test. The company plans to report to the FDA in the coming weeks, says Albert Bourla’s chief executive officer, “I hope to start vaccinating this year before school starts.”
If it wins an emergency permit, Pfizer vaccine will be the first in the United States to be given to children under the age of 16. believe it that childhood vaccines are very important in achieving animal protection – many people are immune to COVID-19 so that the virus can no longer spread properly. President Joe Biden has called for the protection of high school-age children by arriving in the US and early primary in 2022, as test results such as the one announced by Pfizer show that the vaccine is indeed safe and effective among them.
Pfizer said the trial showed that the vaccine was safe for children between the ages of 12 and 15, which had side effects “most closely related to those seen by people aged 16 to 25 years.”
Pfizer vaccine was first approved for emergency use to 16 or more people in December, and more than 75 million species have been given to Americans since then. A clinical trials last fall found that 95% was effective in reducing COVID-19 infections in adults; Recent research has shown 90% of results in “the real world“from the time it was approved.
Announcing this, Pfizer also said it has started vaccinating children between the ages of 5 and 11 on a global test and will begin next week to submit it to a group of children between the ages of 2 and 5.